1. Home
  2. NEXT vs NTLA Comparison

NEXT vs NTLA Comparison

Compare NEXT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

SELL

Current Price

$6.80

Market Cap

2.0B

Sector

Energy

ML Signal

SELL

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

SELL

Current Price

$12.03

Market Cap

1.8B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NEXT
NTLA
Founded
2010
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
NEXT
NTLA
Price
$6.80
$12.03
Analyst Decision
Buy
Buy
Analyst Count
5
20
Target Price
$8.70
★ $23.11
AVG Volume (30 Days)
2.3M
★ 5.1M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.43
EPS
★ N/A
N/A
Revenue
N/A
★ $67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$143.36
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 16.92
52 Week Low
$4.75
$7.95
52 Week High
$9.24
$28.24

Technical Indicators

Market Signals
Indicator
NEXT
NTLA
Relative Strength Index (RSI) 50.20 47.22
Support Level $6.14 $11.49
Resistance Level $7.79 $13.88
Average True Range (ATR) 0.26 0.74
MACD 0.04 0.04
Stochastic Oscillator 83.33 34.79

Price Performance

Historical Comparison
NEXT
NTLA

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas, the sale of LNG, and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions, advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: